Pyrotinib with trastuzumab for HER2-positive breast cancer maintenance
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old.
- Your breast cancer is HER2-positive (a protein that fuels cancer growth) and has spread to other parts of the body or come back after treatment.
- You have not had brain metastases (tumors spread to the brain).
- You are able to take pills by mouth and have no history of serious stomach or bowel problems.
- Your general health is good, with normal blood counts, liver and kidney function, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial tests a combination of three targeted drugs (pyrotinib plus trastuzumab and pertuzumab) as maintenance therapy to help keep advanced HER2-positive breast cancer under control after initial successful treatment. The goal is to see if this triple-drug approach works better than the standard two-drug maintenance.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
This study tests a maintenance therapy (treatment given to keep cancer from growing) for women with HER2-positive breast cancer that has spread or can't be removed. It may help if you haven't had much treatment yet for your advanced cancer.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.